Clinical trials: Cancer of Nasopharynx
Esophageal Cancer, Head and Neck Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002951
- Testing
- fluorouracil, hydroxyurea, surgical procedure
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- University of Chicago
Nasopharyngeal Carcinoma
Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
This is a phase 2, single-arm, multicenter clinical trial, with the purpose to evaluate the therapeutic efficacy, safety, and tolerability of PD-1 Blockade nivolumab combined with a deintensified chemoradiotherapy by sparing…
- Trial name
- PLATINUM (NCT03984357)
- Testing
- PD-1 blocking antibody, Gemcitabine, Cisplatin
- Where
- 6 sites in China
- Volunteers
- 152 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Tobacco Use Disorder
Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use
RATIONALE: A counseling program that motivates patients to stop smoking and drinking may reduce the risk of oral cancer. It is not yet known whether motivational stop smoking counseling or motivational stop-smoking and stop…
- Trial name
- NCT00799669
- Testing
- smoking cessation intervention, counseling intervention, preventive intervention
- Volunteers
- 370 people
- Sponsor
- M.D. Anderson Cancer Center
Radiation-induced Xerostomia
A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)
This study is a single-center, double-blind, randomized controlled clinical trial with placebo as the control, aiming to evaluate the effectiveness of spermidine in preventing radiation-induced xerostomia during radiotherapy for…
- Trial name
- NCT07035626
- Testing
- Spermidine, Spermidine simulants
- Where
- China
- Volunteers
- 58 people
- Sponsor
- West China Hospital
Nasopharyngeal Carcinoma
Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of a combination of GP chemotherapy and Penpulimab ± Anlotinib in neoadjuvant therapy combined with Penpulimab in adjuvant therapy of locoregionally advanced…
- Trial name
- NCT05193617
- Testing
- GP+Penpulimab+Anlotinib, GP+Penpulimab
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer
Current therapies for advanced Head and Neck Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of advanced Head and Neck…
- Trial name
- NCT00003489
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Burzynski Research Institute
Nasopharyngeal Carcinoma by AJCC V9 Stage
Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma
This is a randomized, phase III, prospective, multi-center trial in newly diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis.
- Trial name
- NCT07268690
- Testing
- Omission of Level Va Irradiation in Nasopharyngeal Carcinoma
- Where
- China
- Volunteers
- 474 people
- Sponsor
- Fujian Cancer Hospital
Advanced Nasopharyngeal Carcinoma
GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma
Mainly compared with GP induction chemotherapy combined with IMRT and TPF induction chemotherapy combined with IMRT in the treatment of nasopharyngeal carcinoma, the cure rate, remission rate, treatment of distant metastases and…
- Trial name
- NCT03723343
- Testing
- GP+IMRT, TPF+IMRT
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Guiyang Medical University
Head and Neck Cancer
Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01194635
- Testing
- fluorescence in situ hybridization, gene expression analysis, polymerase chain reaction
- Volunteers
- 69 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Nasopharyngeal Carcinoma
Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare induction chemotherapy (gemcitabine+cisplatin) plus concurrent chemoradiotherapy with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC)…
- Trial name
- NCT01417390
- Testing
- Drug: Gemcitabine and cisplatin, Cisplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- First People's Hospital of Foshan
Nasopharyngeal Carcinoma
Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
A total of 300 patients with pathologically confirmed Locoregionally advanced nasopharyngeal carcinoma were enrolled. Patients were randomly divided into two groups, with 150 patients in each group.
- Trial name
- NCT02907710
- Testing
- Endostar, DDP
- Where
- China
- Volunteers
- 300 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma
Combining PET/CT and EBV DNA to Evaluate the Hazard of Progression in the Follow-up of Locally Advanced NPC
PET/CT and EBV DNA are important in diagnosis of NPC. We consider that combining post-treament PET/CT and plasma EBV DNA may be effective in evaluating the hazard of progression in the follow-up of Locally Advanced Nasopharyngeal…
- Trial name
- NCT03601390
- Testing
- PET/CT and EBV DNA
- Where
- China
- Volunteers
- 387 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma
This is a prospective, single-center, single-arm, phase II clinical study. The study was intended to include patients with locoregionally advanced nasopharyngeal cancer identified by histology or cytology, who signed informed…
- Trial name
- NCT06364826
- Testing
- Sintilimab, bevacizumab, gemcitabine, IMRT
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Stage IV Gastric Carcinoma, Stage IV Nasopharyngeal Carcinoma
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
This study will evaluate the safety of PD-1 knockout EBV-CTL cells in treating EBV (Epstein-Barr virus) positive advanced stage malignancies. Blood samples will also be collected for research purposes.
- Conditions
- Stage IV Gastric Carcinoma, Stage IV Nasopharyngeal Carcinoma, T-Cell Lymphoma Stage IV, Stage IV Adult Hodgkin Lymphoma
- Trial name
- NCT03044743
- Testing
- Fludarabine, Cyclophosphamide, Interleukin-2
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Yang Yang
Nasopharyngeal Carcinoma
Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma
This is a Phase III randomized controlled multi-center trial comparing anlotinib plus Gemcitabine/Cisplatin with placebo plus Gemcitabine/Cisplatin in previous untreated patients with recurrent/metastatic Nasopharyngeal…
- Trial name
- NCT03601975
- Testing
- Gemcitabine/Cisplatin
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Head and Neck Cancer
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
RATIONALE: Collecting and storing samples of tissue, saliva, and blood from patients with cancer and from healthy participants to study in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00898638
- Testing
- biologic sample preservation procedure, medical chart review
- Where
- 4 sites in United States
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Nasopharyngeal Carcinoma (NPC)
The Effectiveness of Structured Swallowing Exercise Therapy in Patients With Nasopharyngeal Carcinoma: An Assessment of Swallowing Function and Quality of Life
This study aims to evaluate the effectiveness of a structured swallowing exercise program compared with conventional swallowing exercises in patients with nasopharyngeal carcinoma.
- Trial name
- NCT07909538
- Testing
- Structured Swallowing Exercise, Conventional Swallowing Exercise
- Where
- Indonesia
- Volunteers
- 88 people
- Sponsor
- Ira Mistivani, dr. Sp.KFR.N.M.(K).
Nasopharyngeal Carcinoma, Herpesvirus 4, Human
Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
The investigators aim to explore a new EBV DNA surveillance method with both high sensitivity and specificity in nasopharyngeal carcinoma (NPC) patients.
- Trial name
- NCT06321939
- Testing
- EBV-DNA next generation sequencing
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hunan Cancer Hospital
Nasopharyngeal Neoplasms, Carcinoma, Squamous Cell
Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0)
To test the therapeutic ratio of accelerated radiotherapy and/or chemotherapy on locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT00563862
- Testing
- Conventional RT, Accelerated RT, Cisplatin
- Where
- 5 sites in China
- Volunteers
- 465 people
- Sponsor
- Hospital Authority, Hong Kong
Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This randomized phase I/II trial is to see if combining erlotinib with bevacizumab works better in treating patients who have recurrent or metastatic head and neck cancer.
- Conditions
- Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx
- Trial name
- NCT00055913
- Testing
- bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.